Login
Navigate Fool.com
Will QCOR beat
the market?
Community Rating: 2 Stars: Unattractive

80.07 1.93 (2.47%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $77.44
Previous Close $78.14
Daily Range $76.75 - $80.24
52-Week Range $28.27 - $85.69
Market Cap $4.9B
P/E Ratio 16.42
Dividend (Yield) $1.20 (1.5%)
Ex-Dividend Date
Dividend Pay Date
06/27/14
07/08/14
Volume 1,647,748
Average Daily Volume 3,287,950
Current FY EPS $7.92

How do you think QCOR
will perform against the market?

Top QCOR Bull/Bear Pitches

 

SnowBawl (0.97)
Submitted October 23, 2011

#1 best small public company.

0 Replies Reply Report this Post
 

tenmiles (< 20)
Submitted November 13, 2007

technical short after pop on MS drug sales growth - current price unsustainable

1 Replies Reply Report this Post

News & Commentary Rss Feed

5 Unlikely Companies Bucking the Biotech Sell-Off

The SPDR S&P Biotech ETF is down 22.4% over the trailing month, but these five biotech stocks are all up. What's their secret?

3 Humongous Health-Care Stocks This Week

The bubbles of some biotechs look to be floating up in the air instead of bursting. These three health-care stocks enjoyed humongous gains this week.

5 of Last Week's Biggest Winners

These five stocks posted double-digit percentage gains.

This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere

A surprise buyout, MannKind's sanguine PDUFA update regarding Afrezza, and three positive clinical studies, mark this week's top biotech stories.

Questcor Buyout Shocks Short Sellers

Questcor's surprise deal with Mallinckrodt causes a huge problem for short sellers.

Mallinckrodt plc Takes a Big Swing for Growth

In buying Questcor, Mallinckrodt is acquiring exceptional potential for earnings, controversy, and disappointment

Top Analyst Upgrades and Downgrades: ARM, Cisco, FireEye, Nike, Twitter, Yelp and More

2014's Most Shocking Takeover

The Verdict is in: Questcor Pharmaceuticals Bulls Win, Bears Lose

Is There a Lesson to Be Learned in Mallinckrodt's Questcor Deal?

Here's what you need to know about why Mallinckrodt bought the heavily shorted Questcor (QCOR) for more than $5.5 billion.

Why Vocus, Agios Pharmaceuticals, and Questcor Pharmaceuticals Are Today's 3 Best Stocks

The S&P 500 gets rocked for a second straight session while Vocus, Agios, and Quesctor all soar by double digits.

See More QCOR News...

Sector

Healthcare

Industry

Drugs

Questcor Pharmaceuticals (QCOR) Description

A pharmaceutical company that focuses on novel therapeutics for the treatment of diseases and disorders of the central nervous system. Website: http://www.questcor.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks